Efficacy and safety of regorafenib in the treatment of bone sarcomas: systematic review and meta-analysis.

IF 3.4 2区医学 Q2 ONCOLOGY BMC Cancer Pub Date : 2025-02-19 DOI:10.1186/s12885-025-13722-y

Yuanhang Han, Jiangtao Xie, Yuyang Wang, Xiaoxiao Liang, Yuanlong Xie

{"title":"Efficacy and safety of regorafenib in the treatment of bone sarcomas: systematic review and meta-analysis.","authors":"Yuanhang Han, Jiangtao Xie, Yuyang Wang, Xiaoxiao Liang, Yuanlong Xie","doi":"10.1186/s12885-025-13722-y","DOIUrl":null,"url":null,"abstract":"Background: Metastatic or recurrent bone sarcomas are often associated with an unfavorable prognosis, posing a formidable challenge in extending patients' survival. Currently, regorafenib has shown promise in treating metastatic and recurrent bone sarcomas. However, there is a lack of consensus on its efficacy and safety. This systematic review and meta-analysis aims to consolidate existing data to assess the efficacy and safety of regorafenib in bone sarcomas.Methods: A comprehensive search strategy utilizing MeSH terms and free-text keywords was employed to systematically search the Embase, PubMed, Web of Science, and Cochrane databases up to May 26, 2024. Randomized controlled trials investigating regorafenib monotherapy for metastatic or recurrent bone sarcomas were included. The primary outcomes of interest were progression-free survival (PFS), overall survival(OS) and adverse events (AEs).Results: We retrieved 335 articles and included 5 of them. Regorafenib significantly extended PFS-3 months and PFS-6 months in patients with metastatic or recurrent bone sarcomas compared to the control group, exhibiting a favorable odds ratio (OR) of 2.04 (95% CI: 1.21-2.86, P < 0.01) and 1.03 (95% CI: 0.08-1.99, P < 0.05), respectively. However, regorafenib did not improve OS at any observation point compared with the control group(P > 0.05), and the frequency of AEs was higher, with an odds ratio of 1.35 (95% CI: 0.63-2.07, P < 0.01).Conclusion: Regorafenib emerges as a promising therapeutic option for metastatic or recurrent bone sarcomas, demonstrating certain clinical benefits alongside manageable adverse reactions. Nevertheless, further research is warranted to refine the efficacy and safety profile of regorafenib, particularly in exploring safe dosage ranges or alternative treatment modalities.Registration number: CRD42024551705.","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"302"},"PeriodicalIF":3.4000,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11841194/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12885-025-13722-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Metastatic or recurrent bone sarcomas are often associated with an unfavorable prognosis, posing a formidable challenge in extending patients' survival. Currently, regorafenib has shown promise in treating metastatic and recurrent bone sarcomas. However, there is a lack of consensus on its efficacy and safety. This systematic review and meta-analysis aims to consolidate existing data to assess the efficacy and safety of regorafenib in bone sarcomas.

Methods: A comprehensive search strategy utilizing MeSH terms and free-text keywords was employed to systematically search the Embase, PubMed, Web of Science, and Cochrane databases up to May 26, 2024. Randomized controlled trials investigating regorafenib monotherapy for metastatic or recurrent bone sarcomas were included. The primary outcomes of interest were progression-free survival (PFS), overall survival(OS) and adverse events (AEs).

Results: We retrieved 335 articles and included 5 of them. Regorafenib significantly extended PFS-3 months and PFS-6 months in patients with metastatic or recurrent bone sarcomas compared to the control group, exhibiting a favorable odds ratio (OR) of 2.04 (95% CI: 1.21-2.86, P < 0.01) and 1.03 (95% CI: 0.08-1.99, P < 0.05), respectively. However, regorafenib did not improve OS at any observation point compared with the control group(P > 0.05), and the frequency of AEs was higher, with an odds ratio of 1.35 (95% CI: 0.63-2.07, P < 0.01).

Conclusion: Regorafenib emerges as a promising therapeutic option for metastatic or recurrent bone sarcomas, demonstrating certain clinical benefits alongside manageable adverse reactions. Nevertheless, further research is warranted to refine the efficacy and safety profile of regorafenib, particularly in exploring safe dosage ranges or alternative treatment modalities.

Registration number: CRD42024551705.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

瑞非尼治疗骨肉瘤的疗效和安全性：系统评价和荟萃分析。

背景：转移性或复发性骨肉瘤通常伴有不良预后，对延长患者的生存期提出了巨大的挑战。目前，瑞非尼在治疗转移性和复发性骨肉瘤方面显示出前景。然而，对其有效性和安全性缺乏共识。本系统综述和荟萃分析旨在巩固现有数据，以评估瑞非尼治疗骨肉瘤的有效性和安全性。方法：采用基于MeSH术语和自由文本关键词的综合检索策略，系统检索Embase、PubMed、Web of Science和Cochrane数据库，检索时间截止到2024年5月26日。随机对照试验调查瑞非尼单药治疗转移性或复发性骨肉瘤。主要研究终点为无进展生存期（PFS）、总生存期（OS）和不良事件（ae）。结果：我们检索到335篇文献，其中5篇被纳入。与对照组相比，瑞非尼显著延长转移性或复发性骨肉瘤患者的PFS-3个月和PFS-6个月，优势比（or）为2.04 (95% CI: 1.21-2.86, P 0.05)，不良事件发生率更高，优势比为1.35 （95% CI: 0.63-2.07， P）。瑞非尼作为转移性或复发性骨肉瘤的一种有希望的治疗选择，显示出一定的临床益处和可控的不良反应。然而，需要进一步的研究来完善瑞非尼的疗效和安全性，特别是在探索安全剂量范围或替代治疗方式方面。注册号：CRD42024551705。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

BMC Cancer 医学-肿瘤学

CiteScore

6.00

自引率

2.60%

发文量

1204

审稿时长

6.8 months

期刊介绍： BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.